Curanex Pharmaceuticals
CURX
2 hedge funds and large institutions have $65.7K invested in Curanex Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 9 closing their positions.
0.35% less ownership
Funds ownership: 1.18% → 0.83% (-0.35%)
43% less capital inflows, than outflows
Capital inflows: $36.3K | Capital outflows: $63.5K
82% less funds holding
Funds holding: 11 → 2 (-9)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$33.1K |
| 2 |
Tower Research Capital (TRC)
New York
|
+$3.19K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu Financial
New York
|
-$14K |
| 2 |
Renaissance Technologies
New York
|
-$13.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$10.2K |
| 4 |
Jane Street
New York
|
-$8.28K |
| 5 |
Two Sigma Investments
New York
|
-$7.25K |
CURX Hedge Fund Activity: Q3 2026 in Review
2 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Curanex Pharmaceuticals (CURX) for Q3 2026, worth a combined $65.7K — down 26% from $89K a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CURX and 0 opened new positions — a net loss of 9 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, adding an estimated $33.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $14K sold.
- 2 institutional investors held Curanex Pharmaceuticals (CURX) as of Q3 2026, down from 11 in Q2 2026.
- Funds reported $65.7K of Curanex Pharmaceuticals stock for Q3 2026, down 26% quarter-over-quarter.
- 0 funds opened new Curanex Pharmaceuticals positions in Q3 2026 and 9 closed out, a net change of -9 holders.
- The largest Curanex Pharmaceuticals buyer in Q3 2026 was Citadel Advisors, an estimated $33.1K added.
- The largest Curanex Pharmaceuticals seller in Q3 2026 was Virtu Financial, an estimated $14K sold.
Based on aggregated 13F filings for Q3 2026.